The new remdesivir data from Tony Fauci from N >1,000 placebo-controlled trial (unpublished, Oval Office citation) does not show statistically significant reduction in mortality (8% vs 11%, in the right direction) but a clear-cut benefit in time to recovery 11 vs 15 days, P<0.001

Fortunately, there are no new strains of #SARSCoV2. Just changes in the letters of its RNA, a slow evolution, that enables precise genomic detective work, tracking of spread from one place to another. A great explainer: nytimes.com/interactive/20… Jonathan Corum Carl Zimmer NYT Science

Our case report re-creating the original antegrade transeptal approach to TAVR using an AV rail with long 26 French sheath to protect the septum and mitral valve. Might be a viable alternative access in selected patients.

Abnormal aortic cusps - how to do they influence TAVR deployment?

#productivity

Since everyone is talking reform, dear editors plz consider 1.Standardize submission processes 2.Pick reviewers/AEs who judge study quality not its fitting w their views 3. 3-months for a decision is too long 4.Allow >24h 2edit the proofs. #cardiotwitter plz add to the wish list!

Check out our article: Novel Use of Echo Fusion and Cardiac Computed Tomographic Imaging Guidance for Percutaneous Paravalvular Leak Closure ⁦CV Case Journal⁩ ⁦Tilak Pasala⁩ ⁦@HackensackUMC⁩ ⁦American Society of Echocardiography⁩ cvcasejournal.com/article/S2468-…

Hemodynamic effects of reducing tricuspid regurgitation from torrential to mild-moderate with 3 MitraClip XTW. Pressure tracings recorded via the clip G4 guide. #tricuspid @SorinVPislaru @michelenahector Trevor Simard Abdallah El Sabbagh Stephanie El Hajj Younes MD Kashish Goel @drpaulfriedman

Second part of @drmortkern’s lecture focusing on “Intracoronary physiology” during Iowa Chapter of the American College of Cardiology and ACC Early Career Section “Interventional Cardiology Board Review”. American College of Cardiology Mahi Ashwath Poonam Velagapudi Shubha Deep Roy, MD, FACC, FASE, FASNC, FSCAI Meera Kondapaneni Tilak Pasala

Thank you Ancora Heart for a great training session today! Looking forward to December! Tilak Pasala @dudiyyuriy

Lucy Tilak Pasala @dudiyyuriy Thank you Lucy, Tilak, Yuriy, and entire @HackensackUMC team for a very productive day and great start to the CorCinch-HF Pivotal Study

Substack(#2) Determining the TAVR Valve Stock Inventory in Hospitals Leveraging math fundamentals and data analysis can drive informed TAVR valve stock inventory decisions. Greater efficiency ==> Better outcomes. #structuralheart #tavr #probability #BusinessOperations

Substack(#3) Artificial Intelligence in Healthcare (Part 1): Terminology and Fundamentals open.substack.com/pub/tilakpasal… In this multiple-part series (most likely, fingers crossed), join me in learning about AI in Healthcare. We will start with understanding the basic terminology and

Substack(#4) - Artificial Intelligence in Healthcare (Part 2): Scope of Large Language Models (LLMs) open.substack.com/pub/tilakpasal… Check out a customized chatGPT-4 for PubMed searches I have been working on - chat.openai.com/g/g-0e7Ms1sjv-… #ArtificialInteligence #LLMs #healthcare

Substack(#5) - Artificial Intelligence in Healthcare (Part 3): Medical Image Analysis and Applications - I open.substack.com/pub/tilakpasal… AI in Healthcare series Part 1: Terminology and Fundamentals - open.substack.com/pub/tilakpasal… 2: Scope of Large Language Models - open.substack.com/pub/tilakpasal…